FDA approves Wegovy for chronic weight management

The U.S. Food and Drug Administration approved Wegovy (semaglutide) injection on June 4, 2021 for chronic weight management in adults, making it the first semaglutide product cleared in the United States for weight loss rather than diabetes ^[1][3].

FDA records list the approval under new drug application NDA 215256, original submission 1, with a status date of June 4, 2021 and a "priority" review designation ^[4]. The application was classified as "Type 10 — New Indication Submitted as Distinct NDA — Not Consolidated," the pathway used when a company files an existing molecule for a new use as its own separate application ^[4]. The approval letter and the first Wegovy label were posted to FDA's public database on June 7, 2021 ^[4].

What was approved

Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist made by Novo Nordisk ^[1]. The injection is given under the skin once a week, in the abdomen, thigh, or upper arm, with or without meals ^[1]. Wegovy injection pens have been marketed in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg strengths, with 2.4 mg as the full maintenance dose for weight management ^[3].

Semaglutide itself was not new in 2021. The same molecule had already been approved as Ozempic injection for type 2 diabetes on December 5, 2017, and as Rybelsus tablets for type 2 diabetes on September 20, 2019 ^[3]. That history explains an inconsistency in the sources: an FDA web page about a later Wegovy approval states that Wegovy "was first approved in 2017," while FDA's own application database and Drugs.com both date the first Wegovy approval to June 4, 2021 ^[2][1][4]. The 2017 date matches Ozempic, not Wegovy ^[3].

The supporting evidence included a 68-week trial of semaglutide 2.4 mg in adults with obesity, reported in March 2021, in which participants achieved and maintained significant weight loss ^[1]. The specific percentage weight change from that trial is not stated in the sources provided here.

Safety information on the label

The Wegovy label carries a boxed warning for an increased risk of thyroid C-cell tumors ^[1]. Warnings and precautions listed on the current label include acute pancreatitis, acute gallbladder disease, low blood sugar, acute kidney injury, hypersensitivity reactions, diabetic retinopathy complications in people with type 2 diabetes, increased heart rate, suicidal behavior and ideation, and pulmonary aspiration during general anesthesia or deep sedation ^[1]. Common side effects reported at 5% or more include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, indigestion, dizziness, bloating, burping, gas, reflux, and cold symptoms ^[1][2]. People with a personal or family history of medullary thyroid cancer, with multiple endocrine neoplasia type 2, or with known sensitivity to semaglutide or Wegovy's ingredients should not take the drug ^[2]. Labels are updated over time, and some of these items were added after 2021 ^[4].

Why it matters for patients

Before this approval, people seeking a prescription GLP-1 for weight had no semaglutide product carrying a weight-management indication, which matters for insurance coverage, pharmacy dispensing, and off-label prescribing conversations. A labeled indication is what payers and prescribers generally point to when deciding how a drug can be used and paid for.

The approval also set up the naming confusion that still trips people up: Ozempic and Rybelsus are semaglutide for type 2 diabetes, while Wegovy is semaglutide for weight and, later, other uses ^[3]. The label specifically says using Wegovy together with another semaglutide product or another GLP-1 receptor agonist is not recommended ^[1].

What happened next

FDA records show a steady expansion of the Wegovy label after 2021: approval for adolescents aged 12 and older with obesity on December 23, 2022; cardiovascular risk reduction in adults with established cardiovascular disease and overweight or obesity on March 8, 2024, based on the SELECT trial, which showed a 20% reduction in major adverse cardiovascular events; accelerated approval for noncirrhotic MASH with stage F2–F3 fibrosis on August 15, 2025; and approval of Wegovy tablets for weight management on December 22, 2025 ^[1][4]. A higher-dose Wegovy HD 7.2 mg injection was approved March 19, 2026 ^[1].